2Seventy Bio

$16.47 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About 2Seventy Bio

2Seventy Bio, Inc. is a cell and gene therapy company. The Company is focused on the research, development, and commercialization of transformative treatments for cancer. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. It is advancing multiple preclinical and clinical programs in oncology. The Company's lead preclinical programs in B cell non-Hodgkin's lymphoma (B-NHL) and acute myeloid leukemia are illustrations of its multiplex approach applied to address the specific challenges of treating those cancers. It is developing bbT369 product candidate as a treatment for patients with B-NHL.

Stock Analysis

last close $16.59
1-mo return 28.6%
3-mo return 52.1%
avg daily vol. 434.03T
52-week high 64
52-week low 9.91
market cap. $625M
forward pe -
annual div. -
roe -134.5%
ltg forecast -
dividend yield -
annual rev. $55M
inst own. 84.6%
baraka

Subscribe now for daily local and international financial news

Subscribe